10 Best Performing American Stocks in June 2026
Fidelity says “Market breadth has broadly remained strong” and “unrelenting corporate earnings growth has underpinned stocks.” That suggests some recent rallies are happening in a market still...
Kymera Therapeutics Inc. (KYMR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 8,657,242 | $992,725,940 | 4.97% | |
| 2. | VenBio Select Advisor Kurt Von Emster | 7,474,747 | $857,129,238 | 7.7% | |
| 3. | Biotechnology Value Fund / BVF Inc Mark Lampert | 3,872,052 | $444,008,203 | -30% | 11.35% |
| 4. | Siren L.L.C. Raymond Debbane | 2,935,830 | $336,651,626 | -8% | 6.81% |
| 5. | Driehaus Capital Richard Driehaus | 919,233 | $105,408,448 | -12% | 0.61% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $86.00 | 1,838,621 | $158,121,406.00 | 7,955,916 | 2025-12-11 | Filing | |
| $86.00 | 167,192 | $14,378,512.00 | 701,326 | 2025-12-11 | Filing | |
| $44.00 | 58,780 | $2,586,320.00 | 353,412 | 2025-06-30 | Filing | |
| $44.00 | 115,783 | $5,094,452.00 | 2,219,858 | 2025-06-30 | Filing | |
| $44.00 | 142,604 | $6,274,576.00 | 2,798,795 | 2025-06-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $119.00 | 50,000 | $5,950,000.00 | 666,568 | 2026-07-07 | Filing | |
| $117.70 | 3,200 | $376,649.28 | 244,883 | 2026-06-30 | Filing | |
| $116.99 | 6,153 | $719,862.24 | 248,083 | 2026-06-30 | Filing | |
| $115.82 | 7,971 | $923,178.10 | 254,236 | 2026-06-30 | Filing | |
| $114.77 | 51,375 | $5,896,288.20 | 262,207 | 2026-06-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,349,256 | $1,416,089,213 | 0.06% | |
| 2. | 5,538,210 | $635,066,535 | 0.01% | |
| 3. | 3,675,028 | $421,415,461 | 0.07% | |
| 4. | 2,992,193 | $343,114,771 | 0.02% | |
| 5. | 2,932,378 | $336,255,785 | 0.01% |
News See All
10 Best AI Driven Biotech Stocks to Invest In
In this article, we will take a look at some of the best AI driven biotech stocks that are currently offering attractive upside potential.
Is Kymera Therapeutics, Inc. (KYMR) a Long-Term Biotech Winner After New Buy Rating and Coverage Launch At Canaccord?
TheFly reported on May 6 that Canaccord initiated coverage on KYMR with a Buy rating and a price target of $106.
8 Best Immunology Stocks to Buy According to Hedge Funds
Despite growing geopolitical tensions related to the Iran war, Callanish Capital CEO Haig Bathgate shared an optimistic stance on global markets during an appearance on CNCB on May 7.
FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)’s KT-621 for Eosinophilic Asthma
TheFly reported on April 13 that KYMR announced that the U.S.
Top 10 AI-Powered Biotech Stocks to Buy Right Now
Franklin Equity reported on February 16 that, following a protracted period of uncertainty in the previous year, the biotechnology sector has entered 2026 on a firmer and more stable foundation.
15 Most Promising Stocks Under $100 to Buy
On March 12, Roger Ferguson, former Fed Vice Chair, joined 'Closing Bell' on CNBC to discuss what to expect from the Federal Reserve next week.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2025 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2025 Earnings Call Transcript February 26, 2026Kymera Therapeutics, Inc. misses on earnings expectations.
Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is among the 14 best booming stocks to buy right now.
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
Hedge Fund Resource Center